Hoffmann-La Roche Inc.

F. Hoffmann-La Roche Ag

Steven Joseph Berthel

Robert Francis Kester

Jefferson Wright Tilley

Lucja Orzechowski

Yimin Qian

Ramakanth Sarabu

Nancy-Ellen Haynes

Kshitij Chhabilbhai Thakkar

Buelent Kocer

Stephen Deems Gabriel

Yan Lou

Xiaochun Han

Thomas Jay Prins

Li Chen

Zachary Kevin Sweeney

Timothy D Owens

Fariborz Firooznia

Roland Joseph Billedeau

Christine E Brotherton-Pleiss

Kyungjin Kim

Douglas Eric Murphy

Saul Jaime-Figueroa

Jenny Tan

Ramona Hilgenkamp

Sung-Sau So

Jean-Marc Plancher

Matthew C Lucas

Francisco Javier Lopez-Tapia

Chinh Viet Tran

Peter Michael Wovkulich

Frank Ruebsam

Dionisios Vourloumis

Nathan Robert Scott

Lee Apostle McDermott

Shawn David Erickson

Lichun Feng

Steven Gregory Mischke

Elbert Chin

Nader Fotouhi

Weiya Yun

Wendy Lea Corbett

Eric Mertz

Adrian Wai-Hing Cheung

Zhi Chen

John A Brinkman

Stuart Hayden

Daniel Fishlock

Hong Wang

Feng Chi

Jun-Bae Hong

Robert J Weikert

David Shawn Erickson

Thimothy D Owens

The present invention discloses compounds of Formula (I): wherein the variables in Formula (I) are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula (I) in the prevention or treatment of HCV infection. 

Antiviral compounds

This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Inhibitors of bruton's tyrosine kinase

The present invention relates to compounds of the formula I, as well as pharmaceutically-acceptable salts thereof, pharmaceutical compositions containing said compounds and methods of using said compounds in the treatment or prophylaxis of diseases and disorders. The compounds and compositions disclosed herein are glucokinase activators useful for the treatment or prophylaxis of metabolic diseases and disorders, for example diabetes mellitus, including type II diabetes mellitus.

Isoindolinone derivatives

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

Pyridazinone glucokinase activators

Azaindole glucokinase activators

Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.

Pyrazole glucokinase activators

Disclosed herein are pyrazole glucokinase activators of the formula (I): that are useful for the treatment of metabolic diseases and disorders.

Oxime glucokinase activators

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of obesity, hyperphagia, anxiety, depression and related disorders and diseases.

MCH receptor antagonists

Pyrrolidinone glucokinase activators

The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds which are useful for inhibiting protein tyrosine phosphatases, particularly PTP1B, and are useful for lowering blood glucose concentrations in mammals.

Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors

This invention relates to diaminopyrroloquinazoline compounds which are useful for inhibiting protein tyrosine phosphatases, particularly PTP1B, and are useful for lowering blood glucose concentrations in mammals.

Growing community of inventors

Mendham Township, NJ, United States of America

Steven Joseph Berthel